PGR and non-small cell lung carcinoma: Preclinical studies investigated the anticancer properties of mifepristone in bone, nervous tissue, osteosarcoma, and non-small cell lung carcinoma (NSCLC), as its anti-tumorigenic effects were understood to occur irrespective of PR expression [16].